Department of Plastic Reconstructive Surgery, Hand Surgery Unit, Azienda Ospedaliero Universitaria delle Marche, 60121 Ancona, Italy.
Orthopaedic and Traumatology 2 Surgery for the Upper Limb and Reconstructive Microsurgery, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, 10126 Turin, Italy.
Medicina (Kaunas). 2023 Jan 31;59(2):273. doi: 10.3390/medicina59020273.
Tendon injury and tendinopathy are among the most frequent musculoskeletal diseases and represent a challenging issue for surgeons as well as a great socio-economic global burden. Despite the current treatments available, either surgical or conservative, the tendon healing process is often suboptimal and impaired. This is due to the inherent scarce ability of tendon tissue to repair and return itself to the original structure. Recently, Adipose-derived mesenchymal stem cells (ADSC) and stromal vascular fraction (SVF) have gained a central interest in the scientific community, demonstrating their effectiveness in treatments of acute and chronic tendon disorders in animals and humans. Either enzymatic or mechanical procedures to obtain ADSC and SVF have been described and used in current clinical practice. However, no unified protocols and processes have been established. This systematic review aims at providing a comprehensive update of the literature on the clinical application of ADSC enzymatically or mechanically processed to obtain SVF, alone and in association with biomaterials in the local treatment of tendinopathy and tendon injury in vivo, in animal models and humans. The study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Thirty-two articles met our inclusion criteria, with a total of 18 studies in animals, 10 studies in humans and 4 studies concerning the application of biomaterials in vivo in animals. The review of the literature suggests that ADSC/SVF therapy can represent a promising alternative in tendonregenerative medicine for the enhancement of tendon healing. Nevertheless, further investigations and randomized control trials are needed to improve the knowledge, standardize the procedures and extend the consensus on their use for such applications.
肌腱损伤和肌腱病是最常见的肌肉骨骼疾病之一,对外科医生来说是一个挑战,也是一个巨大的全球社会经济负担。尽管目前有手术或保守治疗可供选择,但肌腱愈合过程往往不理想且受损。这是由于肌腱组织本身修复和恢复到原始结构的能力有限。最近,脂肪来源间充质干细胞(ADSC)和基质血管部分(SVF)在科学界引起了广泛关注,证明了它们在治疗动物和人类急性和慢性肌腱疾病方面的有效性。已经描述并在当前的临床实践中使用了获得 ADSC 和 SVF 的酶或机械程序。然而,尚未建立统一的协议和流程。 本系统评价旨在提供关于使用酶或机械方法处理 ADSC 以获得 SVF 单独或与生物材料联合用于体内治疗肌腱病和肌腱损伤的文献的全面更新,包括在动物模型和人类中的临床应用。该研究根据系统评价和荟萃分析的首选报告项目(PRISMA)进行。 符合纳入标准的有 32 篇文章,其中共有 18 项动物研究、10 项人体研究和 4 项关于生物材料在动物体内应用的研究。文献综述表明,ADSC/SVF 疗法可能是肌腱再生医学中增强肌腱愈合的一种很有前途的替代方法。 然而,需要进一步的调查和随机对照试验来提高认识、规范程序并就其在这些应用中的使用达成共识。